These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
261 related articles for article (PubMed ID: 26023212)
1. Residual HIV-1 replication may impact immune recovery in patients on first-line lopinavir/ritonavir monotherapy. Tran TA; Ghosn J; Avettand-Fenoël V; Hendel-Chavez H; de Goër de Herve MG; Cohen-Codar I; Rouzioux C; Delfraissy JF; Taoufik Y J Antimicrob Chemother; 2015 Sep; 70(9):2627-31. PubMed ID: 26023212 [TBL] [Abstract][Full Text] [Related]
2. Long-term (96-week) follow-up of antiretroviral-naïve HIV-infected patients treated with first-line lopinavir/ritonavir monotherapy in the MONARK trial. Ghosn J; Flandre P; Cohen-Codar I; Girard PM; Chaix ML; Raffi F; Dellamonica P; Ngovan P; Norton M; Delfraissy JF; HIV Med; 2010 Feb; 11(2):137-42. PubMed ID: 19682100 [TBL] [Abstract][Full Text] [Related]
3. Predictors of loss of virologic response in subjects who simplified to lopinavir/ritonavir monotherapy from lopinavir/ritonavir plus zidovudine/lamivudine. Campo RE; Da Silva BA; Cotte L; Gathe JC; Gazzard B; Hicks CB; Klein CE; Chiu YL; King MS; Bernstein BM AIDS Res Hum Retroviruses; 2009 Mar; 25(3):269-75. PubMed ID: 19292590 [TBL] [Abstract][Full Text] [Related]
4. Lopinavir/ritonavir monotherapy or plus zidovudine and lamivudine in antiretroviral-naive HIV-infected patients. Delfraissy JF; Flandre P; Delaugerre C; Ghosn J; Horban A; Girard PM; Norton M; Rouzioux C; Taburet AM; Cohen-Codar I; Van PN; Chauvin JP AIDS; 2008 Jan; 22(3):385-93. PubMed ID: 18195565 [TBL] [Abstract][Full Text] [Related]
5. Dual treatment with lopinavir-ritonavir plus lamivudine versus triple treatment with lopinavir-ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): a randomised, open-label, non-inferiority trial. Arribas JR; Girard PM; Landman R; Pich J; Mallolas J; Martínez-Rebollar M; Zamora FX; Estrada V; Crespo M; Podzamczer D; Portilla J; Dronda F; Iribarren JA; Domingo P; Pulido F; Montero M; Knobel H; Cabié A; Weiss L; Gatell JM; Lancet Infect Dis; 2015 Jul; 15(7):785-92. PubMed ID: 26062880 [TBL] [Abstract][Full Text] [Related]
6. Dual therapy with lopinavir and ritonavir plus lamivudine versus triple therapy with lopinavir and ritonavir plus two nucleoside reverse transcriptase inhibitors in antiretroviral-therapy-naive adults with HIV-1 infection: 48 week results of the randomised, open label, non-inferiority GARDEL trial. Cahn P; Andrade-Villanueva J; Arribas JR; Gatell JM; Lama JR; Norton M; Patterson P; Sierra Madero J; Sued O; Figueroa MI; Rolon MJ; Lancet Infect Dis; 2014 Jul; 14(7):572-80. PubMed ID: 24783988 [TBL] [Abstract][Full Text] [Related]
8. Absence of HIV-1 shedding in male genital tract after 1 year of first-line lopinavir/ritonavir alone or in combination with zidovudine/lamivudine. Ghosn J; Chaix ML; Peytavin G; Bresson JL; Galimand J; Girard PM; Raffi F; Cohen-Codar I; Delfraissy JF; Rouzioux C J Antimicrob Chemother; 2008 Jun; 61(6):1344-7. PubMed ID: 18343806 [TBL] [Abstract][Full Text] [Related]
9. Different kinetics of immunologic recovery using nelfinavir or lopinavir/ritonavir-based regimens in children with perinatal HIV-1 infection. De Luca M; Miccinesi G; Chiappini E; Zappa M; Galli L; De Martino M Int J Immunopathol Pharmacol; 2005; 18(4):729-35. PubMed ID: 16388722 [TBL] [Abstract][Full Text] [Related]
10. HIV-1 viral replication below 50 copies/ml in patients on antiretroviral therapy is not associated with CD8+ T-cell activation. Steel A; Cox AE; Shamji MH; John L; Nelson M; Henderson DC; Gotch FM; Gazzard BG; Kelleher P Antivir Ther; 2007; 12(6):971-5. PubMed ID: 17926652 [TBL] [Abstract][Full Text] [Related]
11. Lopinavir/ritonavir monotherapy as a simplification strategy in routine clinical practice. Moltó J; Santos JR; Negredo E; Miranda C; Videla S; Clotet B J Antimicrob Chemother; 2007 Aug; 60(2):436-9. PubMed ID: 17556354 [TBL] [Abstract][Full Text] [Related]
16. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. Walmsley S; Bernstein B; King M; Arribas J; Beall G; Ruane P; Johnson M; Johnson D; Lalonde R; Japour A; Brun S; Sun E; N Engl J Med; 2002 Jun; 346(26):2039-46. PubMed ID: 12087139 [TBL] [Abstract][Full Text] [Related]
18. Effect of lopinavir/ritonavir monotherapy on quality of life and self-reported symptoms among antiretroviral-naive patients: results of the MONARK trial. Spire B; Marcellin F; Cohen-Codar I; Flandre P; Boue F; Dellamonica P; Raffi F; Norton M; Van Philippe N; Delfraissy JF Antivir Ther; 2008; 13(4):591-9. PubMed ID: 18672538 [TBL] [Abstract][Full Text] [Related]
19. First-line antiretroviral therapy with efavirenz or lopinavir/ritonavir plus two nucleoside analogues: the SUSKA study, a non-randomized comparison from the VACH cohort. Domingo P; Suárez-Lozano I; Torres F; Teira R; Lopez-Aldeguer J; Vidal F; Muñoz A; Viciana P; Lozano F; Vergara A; Roca B; García Alcalde ML; Cosín J; Terrón A; Galindo MJ; Geijo P; Ribera E; Gonzalez J; Sanchez T; Lacalle JR; Garrido M J Antimicrob Chemother; 2008 Jun; 61(6):1348-58. PubMed ID: 18356150 [TBL] [Abstract][Full Text] [Related]
20. A randomized comparison of second-line lopinavir/ritonavir monotherapy versus tenofovir/lamivudine/lopinavir/ritonavir in patients failing NNRTI regimens: the HIV STAR study. Bunupuradah T; Chetchotisakd P; Ananworanich J; Munsakul W; Jirajariyavej S; Kantipong P; Prasithsirikul W; Sungkanuparph S; Bowonwatanuwong C; Klinbuayaem V; Kerr SJ; Sophonphan J; Bhakeecheep S; Hirschel B; Ruxrungtham K; Antivir Ther; 2012; 17(7):1351-61. PubMed ID: 23075703 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]